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Background: Only a handful of signaling pathways are major actors of development and responsible for both the
conservation and the diversification of animal morphologies. To explain this twofold nature, gene duplication and
enhancer evolution were predominantly put forth as tinkering mechanisms whereas the evolution of alternative
isoforms has been, so far, overlooked. We investigate here the role of gain and loss of isoforms using Edaradd,
a gene of the Ecodysplasin pathway, implicated in morphological evolution. A previous study had suggested a
scenario of isoform gain and loss with an alternative isoform (A) newly gained in mammals but secondarily lost in
mouse lineage.
Results: For a comprehensive view of A and B Edaradd isoforms history during mammal evolution, we obtained
sequences for both isoforms in representative mammals and performed in vitro translations to support functional
predictions. We showed that the ancestral B isoform is well conserved, whereas the mammal-specific A isoform was
lost at least 7 times independently in terminal lineages throughout mammal phylogeny. Then, to gain insights into
the functional relevance of this evolutionary pattern, we compared the biological function of these isoforms: i) In
cellulo promoter assays showed that they are transcribed from two alternative promoters, only B exhibiting feedback
regulation. ii) RT-PCR in various tissues and ENCODE data suggested that B isoform is systematically expressed
whereas A isoform showed a more tissue-specific expression. iii) Both isoforms activated the NF-κB pathway in an
in cellulo reporter assay, albeit at different levels and with different dynamics since A isoform exhibited feedback
regulation at the protein level. Finally, only B isoform could rescue a zebrafish edaradd knockdown.
Conclusions: These results suggest that the newly evolved A isoform enables modulating EDA signaling in specific
conditions and with different dynamics. We speculate that during mammal diversification, A isoform regulation
may have evolved rapidly, accompanying and possibly supporting the diversity of ectodermal appendages, while
B isoform may have ensured essential roles. This study makes the case to pay greater attention to mosaic loss of
evolutionarily speaking “young” isoforms as an important mechanism underlying phenotypic diversity and not
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Explaining how species share a common genetic toolkit,
but at the same time show a high phenotypic diversity is
a crucial question of evo-devo [1–3]. Many examples de-
scribed and theorized in the last 30 years have identified
the genetic basis for evolutionary changes such as the
modification of the existing toolkit by mutation (in cod-
ing or regulatory sequence) or its expansion/constriction
by gene duplication and loss [1]. However, with the rise
of omics, other mechanisms that contribute to diversifica-
tion of developmental gene products can now be analyzed
in depth. Among them, the generation of alternative iso-
forms is particularly relevant [4, 5].
Isoforms are generated by alternative splicing sensu
lato (i.e. via differential exon retention, alternative pro-
moters and alternative 3′ splice site) which, is consid-
ered as the most prominent mechanism for generating
mRNA structural complexity [6, 7]. It can produce nu-
merous new gene products that can be differentially reg-
ulated spatio-temporally and translated into proteins
with different functions [8]. The evolution of alternative
isoforms can give rise to new function or sub-function
in different species [9]. Thus, the generation of alterna-
tive isoforms is now considered as an important force in
evolution. Different levels of alternative splicing sensu
lato were described among eukaryotes (and more pre-
cisely in the animal kingdom) [10–12]. Studies that com-
pared transcriptomes between species or tissues have
shown that a significant portion of splicing events are
species-specific [5], suggesting a high turn-over in iso-
form gain and isoform loss and raising the question of
whether the evolution of isoforms is largely neutral.
However the extent to which this quantification is biased
is unclear as datasets often incorporate unwanted spli-
cing events like noisy splicing or regulatory splicing (e.g.
the splicing of an alternative transcript does not result in
encoding another protein but rather in regulating the
abundance of another transcript [9]). Moreover, omics
studies can only rely on very indirect and sometimes cir-
cular arguments (e.g. what is conserved is functional) to
assess the functional significance of detected isoforms, if
any and, the phylogenetic sampling is often very limited
(e.g. mouse/human or a few mammals). In this context,
such omics studies encounter difficulties concluding
about the significance of patterns of isoform gain or loss
during evolution. The field would now greatly benefit
from specific case studies that combine functional ex-
periments and broad phylogenetic sampling. Ideal can-
didates for such studies would be genes known to be
important in phenotypic evolution, and that are likely
to display variation in splice variants in a given group
of species.
Edaradd is one such promising candidate [9]. It en-
codes the intracellular scaffold protein EDARADD (oradaptor) specifically involved in the EDA-A1 pathway. In
all vertebrate species tested so far, this pathway is neces-
sary to the normal formation of ectodermal appendages
(i.e. teeth, scales, hair, feathers, glands…) that are either
missing or malformed in loss of function mutants
[13, 14]. Since ectodermal appendages are hot spots of
adaptation, this pathway is particularly relevant for mor-
phological evolution [13]. It has been repeatedly found
to be involved in morphological evolution, in species as
distant as the stickleback fish and humans [15, 16].
Briefly, this pathway is related to the TNF receptor sig-
naling pathway (Fig. 1A) and is composed by three spe-
cific components: the ligand EDA-A1, the receptor
EDAR and the adaptor EDARADD. EDARADD serves
as a relay between the receptor activated by the ligand
and other intracellular proteins (such as TRAFs) in-
volved in NF-κB pathway regulation, resulting in the ac-
tivation of the NF-κB-dependent transcription upon
ligand binding [17]. In a previous study we have shown
that all three corresponding genes of the EDA-A1 path-
way are highly conserved in vertebrates [18]. Most inter-
estingly, in the context of this study, we had noted that,
while non-mammalian genomes only carry a single iso-
form for the EDARADD adaptor, in mammals this gene
encodes two isoforms, called A and B. The two isoforms
differ by their short N-terminal part encoded by alterna-
tive first exons for detail on the genomic region see
Additional file 1: Figure S1. The B isoform more closely
resembles the isoform found in chicken, although the
limited sampling associated with the short size of the B
peptide did not allow drawing firm conclusions [18]. We
also noted that B isoform is the only isoform found in
mouse and rat [18]. These data therefore suggest a com-
plex history of gain and loss with a newly evolved iso-
form in the mammalian lineage (A isoform), which was
secondarily lost in the mouse/rat lineage.
Thus the Edaradd gene would provide a case study for the
gain and loss of isoforms expressed from alternative pro-
moters in relation to phenotypic evolution. It is quite obvi-
ous that isoform gain and evolution could support
phenotypic evolution (and notably phenotypic innovation),
provided that isoforms have different function or regula-
tion. Because the functional tests to establish the function
of EDARADD (mentioned above) were carried out in
mouse, where the isoform A is absent, or in human, select-
ing the human-mouse conserved B isoform, it is currently
unknown whether the two isoforms have a similar or a very
different function. It is hard to predict just from their se-
quence. On one hand, in terms of domain content, both
isoforms are very similar (Death domain, TRAF binding do-
mains), but on the other hand, a very short N-terminal pep-
tide is in principle sufficient to confer different biochemical
properties, such as different levels of activation or different
downstream signaling. Moreover, in silico predictions [18]
Fig. 1 The EDA pathway and its downstream signaling. a EDA binds EDAR that recruits EDARADD B by interacting with its death domain (DD),
leading to the downstream activation of the NF-κB pathway [17]. EDARADD A displays the same functional domains as EDARADD B but its activity
is not known. Proteins are shown here with a color code that highlights exon 1A/B boundary. b The two isoforms differ by their short N-terminal
part corresponding to the first exon that is close to the TRAF binding sites. Proteins are represented with exon boundaries and exon size (in
amino acid) is indicated. Sequences of the short N-terminal peptide encoded by human exon 1A and 1B are represented in yellow (1A) and
brown (1B)
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from two neighboring but different promoters. Therefore,
besides their biochemical function, they could differ in
terms of transcriptional regulation. Any of these differences
could combine and translate in differential activation of the
EDA pathway depending on the tissue and/or developmen-
tal time that could lead to phenotypic differences in terms
of number and shape of ectodermal appendages. Based on
published data, it is entirely possible that Edaradd isoforms
differ in term of function and/or regulation, yet it remains
to be proven.
When a new isoform is added to an old one during evo-
lution, their ability to sustain phenotypic evolution in the
long term might depend on the way the old and new iso-
form share the core gene function, that were ancestrally
performed by the old isoform. Two extreme scenarios are
possible: In the first, core functions are partitioned between
both isoforms, in which case both may be strongly con-
strained. Alternatively, the ancestral isoform keeps core
functions while the newly evolved isoform has moreaccessory roles, free to evolve in close association with
phenotypic evolution. We expect that the gene will have a
higher ability to support adaptive evolution (i.e. higher evol-
vability) in the latter case than in the former case, and in
the former case than in absence of isoforms. Evaluating
these possibilities for Edaradd not only requires a better
knowledge of A and B isoform function, but firm conclu-
sions about isoform B ancestrality and a broader view of A
and B isoform evolution in mammals.
Therefore, in this study, we questioned the evolution
of A and B isoform in a broader set of mammals than
done previously [18], associating in silico predictions
and bench experiments to firmly conclude about func-
tionality. We showed that B isoform is ancestral and
conserved, while A isoform exhibits an unexpected mo-
saic conservation in mammals, with many independent
losses found during their late diversification. Moreover,
we dissected the respective biochemical function and
regulation of the two isoforms, in a set of experiments
performed in vitro, in cellulo and in vivo. We conclude
Fig. 2 (See legend on next page.)
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Fig. 2 Mosaic conservation of the exon 1A in mammal evolution. a Examination of the exon 1A region in mammals. The yellow box represents
the exon 1A in several mammal species [details in Additional file 6: dataset S6]. In human, two putative ATG could initiate the translation of a
protein. For all species, these ATG are indicated as ATG1 and ATG2 when conserved. When not, the corresponding mutated codon is shown. The
conservation of the promoter, the splice donor site and the frame were also studied and are indicated with symbols. The isoform-A transcript
was detected by RT-PCR in human, guinea pig (Cavia) and wallaby (Macropus) or identified by BLAST against EST databases in macaca and cow
(Bos). Species that are considered to have lost the ability to produce isoform A are shown in red. b In vitro translation experiments. The exon 1A
of Homo [43], Homo mutated for the first ATG (2), Homo mutated for the second ATG [44], Homo mutated for both ATG [43] Cavia (5), Equus (6),
Vicugnia (7) were cloned upstream the Renilla gene to test by in vitro translation their ability to produce a protein from the first exon with different ATG 1
and 2 context. The asterisk shows two faint bands that are the result of low efficiency initiation at a downstream non-specific ATG. The dark red arrow
points out the faint band initiated by an alternative AAG codon for the human double mutant
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regulation, keeping a similar function of NF-κB activation.
We discuss how this combination of similar function and
divergent regulation may enable differential regulation of
the pathway in different developmental contexts, and we
envision a scenario where the regulation of A isoform has
been fast evolving in mammals in parallel with diversifica-
tion of their ectodermal appendages, while B isoform was
maintaining essential functions. We finally argue that iso-
forms generated from alternative promoters as exemplified
by Edaradd could be an underappreciated mechanism en-
suring the stability of some phenotypes and diversification
of others during evolution.
Results
The B isoform of EDARADD is well conserved even
outside mammals
In order to enlarge our previous dataset [18], the genomic
region of the exon 1B was obtained by homology search
(BLAST) against recently published genomes using the re-
gion of the closest available species as a probe. In previous
work, we had suggested that the B isoform of EDARADD
was homologous to the isoform found in chicken, suggest-
ing that the B isoform could be the ancestral isoform
whereas the A isoform would have been gained in mam-
mals [18]. This finding was confirmed here by comparing
sequences obtained from a larger panel of bird species (the
extant vertebrate group closest to mammals). Indeed, both
at the nucleotide and the amino-acid level, the N-terminal
end of the mammalian B isoform exhibits strong similarities
with the N-terminal end of the isoform found in birds [see
Additional file 2: Figure S2]. In addition, the B isoform was
found highly conserved in our upgraded set of 22 mammals
[see Additional file 2: Figure S2]. More specifically, the
promoter, the 5′UTR and the coding region of exon 1B
was found in all genomes, except in some low coverage ge-
nomes for which the genome assembly is obviously incom-
plete in this region.
The A isoform has been repeatedly lost during late
mammal diversification
The picture is different for the A isoform. In previous
work, we had found that the exon 1A producing Aisoform is conserved in a set of mammals but pseudo-
genized in mouse and rat [18]. This prompted us to in-
crease our phylogenetic sampling by adding not only
newly sequenced mammals (as done for B isoform) but
also various rodent species, for which the region was ob-
tained by PCR amplification followed by sequencing
(Fig. 2A). We then aligned the putative promoter 1A
region found ca. 500 bp upstream the ATG and looked
for different criteria enabling functionality prediction,
namely, the conservation of the promoter region, the
splice donor site and the coding region with bona fide
initiation site. In fact, in most species, exon 1A contains
two ATG (here named ATG1 and ATG2) that can po-
tentially initiate the translation: both are in frame and
exhibit a canonical Kozak sequence, an indication of
functionality.
However, a rapid look at this dataset revealed a very
patchy conservation of ATG1 and ATG2: in some spe-
cies (other than mouse and rat), ATG1 or ATG2 or both
we mutated (Fig. 2A). Not only does such patchy conser-
vation raise doubts as to whether a protein can actually
be initiated in this exon 1A, but it is questionable
whether a single ATG will be sufficient when the other
is lost. Therefore, to be able to make realistic predictions
from our dataset, we tested in vitro different constructs
emanating from 4 different species where both ATG are
present or one ATG is lost.
To this end, we cloned wild-type and mutant versions
of the first exon of the A isoform (including the native
5′UTR region known to influence translation efficiency)
upstream of the Renilla reporter gene and performed
in vitro translation (Fig. 2B). For the wild type human
construct (lane 1), we detected two bands that are alter-
natively lost for the single ATG mutant constructs (lanes
2 and 3) and both lost in the double mutant construct
(lane 4). This supports the view that the first (strong)
band corresponds to initiation at ATG1 and the second
(faint) band to a less efficient initiation at ATG2. In such
a test, it is common to observe that the presence of a
potent ATG strongly limits initiation at downstream or
nonspecific initiation sites, as ribosomes will preferen-
tially initiate at the first site that they encounter during
ribosomal scanning. However, if the most 5′ ATG is
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quency at these other sites. This also explains why other
bands are observed in the double mutant (lane 4). In-
deed, we observed two strong much lower bands
(asterix, lane 4) that likely correspond to initiation at
downstream sites, found within the renilla sequence
(note that these two same bands are accordingly also
hardly detected with all other constructs: see lanes 1 to
7). We also observed one faint band (lane 4, dark red
arrow), which is slightly lower than the one seen with
the wild type construct (compare lane 4 with lanes 1 and
3). Here, an analysis of the sequence showed the pres-
ence of a “near cognate AAU” site (an AAG codon),
which is located 3 codons downstream from the ATG1
and was likely recognized by ribosomes, producing this
faint band. With the guinea pig construct containing
both ATG1 and ATG2, we obtained a similar pattern of
initiation as with the wild type human construct (lane
5). Finally, in two species where only the ATG2 remains
(Equus and Vicugna), initiation efficiently occurred at
this site, as it is the case with the human ATG1 mutant
construct (lane 6 and 7). We concluded that ATG1, or
ATG2 (when ATG1 is missing), are potent initiation
sites. As a consequence, we then infer in Fig. 2A that the
A isoform is lost only when the two ATGs are mutated
and/or the promoter region or the splice donor is mu-
tated or absent (species indicated in red in Fig. 2A).
Our analysis revealed that in muroid rodents, the pro-
moter region is completely rearranged: we observed a
deletion of the conserved region where the transcrip-
tional start site is mapped in human, replaced by a 72 bp
insertion (see the red brace encompassing muroid ro-
dents and the red box symbolizing the deletion in
Fig. 2A). Mosaic deleterious events are observed in the
coding sequence (ATG1 and/or ATG2 lost, frame-shift
indels). This pattern strongly suggests that a deletion of
the promoter region occurred in the common ancestor
of muroids and abrogated the transcription of exon 1A
(as observed in mouse, where the pseudogenized exon
1A is not transcribed, [18]). Following this event, con-
straints on the coding sequence were relaxed, leading to
its mosaic degeneration in muroid rodents.
In other mammals, we found other losses (Fig. 2A). In
Ctenomys and Octodon, two rodents that are more
closely related to guinea pig where the A isoform is
expressed [18], frame-shift indel and stop codons are ob-
served. In Echinops, the promoter region exhibits a dele-
tion and a stop codon is found in the coding sequence.
The whole region is lost in Erinaceus and the splice site
is lost in Sus as well as in Sorex. Because these species
belong to very different branches of the mammalian tree
or the mutation events are obviously independent, we
could map at least 7 independent losses (red points in
Fig. 2A). It is noteworthy that isoform-A is found inmarsupials and in all main groups of placental mammals.
Losses occurred later, during the diversification of these
groups, as exemplified in rodents. In the next sections,
we compared the function and regulation of A and B
isoforms.
The two EDARADD isoforms are expressed by two
alternative promoters that are differentially regulated
The existence of two distinct Edaradd mRNA [18] differ-
ing by their first exon suggests that two alternative pro-
moters could control the expression of the two isoforms.
To gain insight into the possible proximal regulation of
the expression of both isoforms, we cloned the 5′ re-
gions of the two putative promoters from two represen-
tative mammalian species upstream of a luciferase
reporter gene and tested them in HEK cells that
expressed both isoforms ([19] and data not shown). We
chose the human gene which has the two isoforms, and
the mouse which has lost the A isoform (Fig. 3A). When
transfected in HEK cells, the B promoter exhibited a
strong activity that was conserved in human and mouse
(Fig. 3C). In contrast, the A promoter exhibited a low
but significant activity (Fig. 3B). Because signaling path-
ways often feedback either positively or negatively [2],
we tested promoter response to the EDA pathway acti-
vation by co-transfecting EDAR that induces an over-
activation of the pathway in cellulo [20] (Fig. 3D and E).
Whereas the A promoter did not exhibit any variation of
its activity compared to the empty vector, the B pro-
moter was downregulated in a dose-dependent manner
by growing amount of transfected EDAR. This downreg-
ulation was observed with other NF-κB activators such
as TRAF6 and partially rescued by NF-κB downregula-
tors such as CYLD (Fig. 3F). It has to be noted that no
cell death was detected during experiments (data not
shown). Taken together, these results show a different
regulation of the two promoters depending on the cellu-
lar context. To further investigate differences in tran-
scriptional regulation in vivo, we studied the expression
of the two isoforms in different tissues from two placen-
tal mammals (human, guinea pig - Cavia porcellus in
Fig. 2A) and a marsupial (tammar wallaby, Macropus
eugenii in Fig. 2A) by RT-PCR experiments and in hu-
man cell lines using the ENCODE data (Fig. 3G). The
two isoforms were generally co-expressed in tissues
and cell lines except in human skin and brain and in
embryonic cell lines in which only the B isoform was
detected. When co-expressed, the two isoforms were
either expressed at the same level or the B isoform
was more strongly expressed than the A isoform. This
shows that the transcripts of A and B isoforms are dif-
ferentially regulated in vivo and in cellulo in line with
the differential regulation of their promoters in lucif-
erase assays.
Fig. 3 The two isoforms of EDARADD are expressed by two differentially regulated alternative promoters. a Scheme of the promoter constructs.
The human promoter A region has no homologous region in mouse. Homo, Homo sapiens; Mus, Mus musculus. b In cellulo test of promoters
activity. Constructs shown in A were transfected in HEK cells. Error bars show variation between triplicates of one out of 3 experiments. Y axis:
normalized luciferase activity against β-galactosidase activity. c In cellulo test of promoters activity. B constructs shown in B were transfected in
HEK cells. Three independent experiments were performed and yielded similar results. One out of these three experiments is shown with error
bars showing variation between triplicates within this given experiment. Y axis: normalized luciferase activity against β-galactosidase activity. d
Promoters response to EDA pathway activation by EDAR co-transfection. Constructs shown in A were co-transfected with increasing amount of
an EDAR expressing plasmid: 0, 50, 100 or 200 ng. Error bars show variation between triplicates in one out of 3 experiments that yielded similar
results. Y axis: normalized luciferase activity against β-galactosidase activity. e Promoters response to EDA pathway activation by EDAR co-transfection. B
constructs were co-transfected with increasing amount of an EDAR expressing plasmid: 0, 50, 100 or 200 ng. Error bars show variation between triplicates
in one out of 3 experiments that yielded similar results. Y axis: normalized luciferase activity against β-galactosidase activity. f Promoter B response to
different NF-κB modulators. The human B promoter was co-transfected with 200 ng of TRAF 6, 200 ng of EDAR only or 200 ng of EDAR
and 200 ng of CYLD supplemented or not by empty vector. Y axe: normalized luciferase activity as in B. g Expression of the two EDARADD
isoforms. Expression of the two isoforms were assayed by RT-PCR in different tissues in human (Homo sapiens), a rodent guinea pig (Cavia
porcellus) and a marsupial tammar wallaby (Macropus eugenii) (AB: A and B detected; B: only B detected; na: not assessed) and in different
human cell lines using ENCODE RNAseq data (A = B : A and B co-expressed at similar levels; B > A: B expressed at higher levels; B: only B is
detected). Cell lines: GM92, NHEK, GM78, H1ES, K562, MCF7, GM91
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the B isoform but accumulates more slowly
To decipher the biochemical role of the two EDARADD
isoforms, we studied the function of the two human pro-
teins in cellulo (Fig. 4) using the same HEK cells. Weused recombination methods to generate expression
plasmids for the two proteins that are rigorously identi-
cal (Fig. 4A), except for the small N-terminal peptide
characterizing the A or B isoform (notably, translation
initiation sites were identical). Since the first known
Fig. 4 The two isoforms of EDARADD exhibit different activities and stabilities in cellulo. a Constructs. HA constructs: HA tag was N-terminally
fused to EDARADD A or B protein. Myc constructs: Myc tag was C-terminally fused to EDARADD A or B protein. These constructs were generated
using recombination so that 1A and 1B constructs only differ for A and B peptide coding region. NF-κB reporter gene: NF-κB are located upstream a
minimal promoter and a luciferase reporter gene. b EDARADD A and B activate the NF-κB pathway in a dose-dependent manner. Increasing amounts of
constructs encoding A or B isoforms were transfected in HEK cells with NF-κB reporter plasmid that harbors NF-κB response elements upstream luciferase
reporter gene. The luciferase activity was normalized against β-gal and the empty vector. The luciferase activity was assayed 24 hours after transfection. In
yellow: isoform A, in brown: isoform B. c A isoform is twice more active than B isoform when luciferase activity is corrected for Edaradd quantity. HEK cells
were transfected with constructs encoding EDARADD A or B C-terminally tagged with myc (EDD-myc A or B) and the luciferase reporter gene as in A.
24 h after transfection, three wells were pooled in order to have enough material for Western Blotting and three others were used for luciferase assays.
Proteins were detected by Western Blot with an anti-Myc antibody. Histone H3 was used as a control. Luciferase activity corrected for edaradd quantity is
presented on the right. d EDARADD A and B reach different steady state levels. HEK cells were transfected with constructs encoding EDARADD A or B
N-terminally tagged with HA (HA-EDD A or B) or C-terminally tagged with myc (EDD-myc A or B). Proteins were detected by Western Blot 12 h, 24 h,
36 h and 48 h after transfection. Histone H3 was used as a control. e EDARADD A but not B is destabilized by NF-κB activators. Western
Blot for Myc C-terminally-tagged A and B isoforms following co-transfection of NF-κB activators such as EDAR or TRAF6, at 24 or 48 h.
Histone H3 is used as a control
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pathway we tested the ability of myc tagged-versions of
both isoforms to activate the NF-κB pathway in a NF-κB
reporter luciferase assay. As previously described, the B
isoform activated the NF-κB pathway reporter in a dose-
dependent manner [19] (Fig. 4B). The A isoform also ac-
tivated the NF-κB pathway reporter in a dose-dependent
manner. Examination of the protein level by western
blot showed that the amount of B isoform was 2.5
higher than the amount of A isoform (Fig. 4C and D).
Similar results were obtained whenever an N-terminal
or a C-terminal tagged version of the proteins was used.
Thus, to compare the activity of both isoforms, theluciferase activity needed to be corrected by the amount
of EDARADD protein detected in the lysates. In so
doing, the A isoform appeared to be twice more active
than the B isoform (Fig. 4C). The co-transfection of the
two constructs together at different concentrations did
not exhibit any synergistic nor antagonistic effect [see
Additional file 3: Figure S3]. We then followed the accu-
mulation of the two proteins for 48 hours and found
that the B isoform accumulated more rapidly than the A
isoform (Fig. 4D). Considering the steady-state level of
the two proteins, at 48 hours, the A isoform disappeared
when co-transfected with EDAR or other NF-κB activa-
tors (Fig. 4E) whereas the B isoform remained stable
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Similar results were obtained in presence of a prote-
asome inhibitor (MG132), presumably ruling out
proteasome-dependent degradation (data not shown). In
summary, the two human isoforms of EDARADD ex-
hibit different functionalities in cellulo: they both acti-
vate the NF-κB pathway but exhibit differences in their
dynamics: the B isoform accumulates more rapidly
whereas the A isoform is more active but downregulated
at the protein level following pathway activation. Such
differences could impact their in vivo functions inFig. 5 Human EDARADD B but not EDARADD A rescues skeletal defects ob
the exon-intron structure of the zebrafish edaradd gene. The location of tar
(MO-spl) edaradd morpholinos is indicated by a red and a green line, respective
expression analysis during development [see Additional file 4: Figure S4] and fo
file 4: Figure S4]. b Knockdown of Edaradd expression leads to skeletal defects. W
was analyzed through alcian blue and alizarin red staining at 5.5 dpf. The larv
normal phenotype. The severe phenotype presented no pharyngeal skeleton
This defect was also accompanied by pericardial and yolk sac edema. Interme
second arch and gill arch derivatives and sometimes one rudimentary tooth o
gill arch derivatives or no obvious defects and at least one tooth on each side
Ventral and lateral views of the head are shown at low magnification (scale b
(scale bar: 100 μm). c Percentages of the various phenotypic groups obtained
control) injection. These results are representative of at least 3 independent e
Human EDARADD A and B mRNA effects in rescuing experiments. One-cell sta
EDARADD A or B, or capped zebrafish edaradd mRNA with at least 70 embryo
phenotypic group in 4 separate experiments and the statistical analyses have
larvae, classified according to their phenotype, are shown for each conditiontransducing the NF-κB pathway both quantitatively and
qualitatively.
The two human isoforms of EDARADD exhibit different
activities in a rescue experiment performed in zebrafish
We next used the zebrafish system to assess if the two
isoforms exhibited functional differences. To this end,
we performed a rescue experiment where endogenous
edaradd function has been obliterated by morpholino
injections but is complemented by isoform A or B
mRNA injections (Fig. 5). It is known that alterations ofserved in MO-injected zebrafish larvae. a Schematic representation of
get sequences for translation-blocking (MO-tsl) and splice-blocking
ly. Blue arrows indicate the location of the primers used for edaradd mRNA
r splice-blocking edaradd MO validation by RT-PCR analysis [see Additional
T embryos were injected at one-cell stage and skeletal morphogenesis
ae phenotypes observed were classified as severe, intermediate or weak/
, a rudimentary neurocranial cartilage and no tooth could be detected.
diate phenotype showed rudimentary pharyngeal skeleton without
n each side of the larvae. Weak/normal phenotype demonstrated small
of the larvae could be clearly observed through alizarin red staining.
ar: 500 μm) and a zoom on the teeth is shown on the right panel
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dermal skeleton development [21], but little is known
about edaradd during early zebrafish development, i.e.
the developmental window mainly targeted by morpho-
lino injections.
Therefore, to help the interpretation of these experi-
ments, we first gathered expression data for the en-
dogenous unique splice variant of edaradd gene during
zebrafish development. By semi-quantitative RT-PCR,
we observed a high maternal expression of edaradd,
which rapidly decreased at 8 hpf (hours post fertilization).
edaradd expression then slowly increased from 12 hpf to
96 hpf [See Additional file 4: Figure S4]. By in situ
hybridization, we could not detect a regionalized edaradd
expression pattern (possibly due to low expression levels)
[Additional file 5: Figure S5] but both eda and edar were
expressed in the pharyngeal region from 48 and 24 hpf re-
spectively, suggesting that the EDA pathway (and therefore
edaradd) was active at least in this region during this
period of zebrafish development.
We next investigated the function of edaradd gene
during zebrafish embryonic development using morpho-
lino antisense oligonucleotides directed either against
edaradd translation initiation site (MO-tsl) to disrupt
the translation of the protein or against edaradd exon 1
splice donor site to disrupt mRNA splicing (MO-spl)
(Fig. 5A). Splice MO efficiency was confirmed by RT-
PCR [see Aditional file 4: Figure S4 for details]. The
edaradd MO-injected larvae exhibited abnormalities of
the pharyngeal and cranial skeleton visible at 5.5 dpf
(days post fertilization) following cartilage and mineral-
ized tissue staining (Fig. 5B and C), consistent with the
expression pattern evidenced for eda and edar. These
embryos were classified depending on the severity of the
skeletal defects and on the presence of teeth (see Fig. 5B
for a detailed description). MO-tsl and MO-spl-injected
larvae led to similar cartilage defects except that MO-spl
had weaker effects, even at high concentrations [see
Additional file 4: Figure S4].
To study the in vivo activities of the two human
EDARADD isoforms, we tested their ability to rescue
the phenotype of the edaradd morphants. We first
checked that injection of EDARADD A or B mRNA or
zebrafish edaradd in wild-type embryos had no obvious
effect even following injection of 100 pg of mRNA per
egg [see Additional file 4: Figure S4]. In particular, no
supernumerary teeth were detected when observed at
5.5 dpf. We then co-injected 25 to 100 pg human EDAR-
ADD A or B or zebrafish edaradd mRNA with MO-tsl
in WT embryos (Fig. 5D and E) and analysed the corre-
sponding larvae as above. We first confirmed that zebrafish
edaradd mRNA efficiently rescued the MO-tsl-induced
skeletal defects. Human EDARADD B mRNA also provided
significant rescue (2.1 ± 1.5 % larvae corresponding to thesevere phenotype for MO-tsl + EDARADD B mRNA-
injected embryos compared to 7.6 ± 3.9 % for MO-tsl-
injected embryos (p = 0.039)). In sharp contrast, EDARADD
A mRNA significantly increased the defects observed in
MO-tsl-injected embryos (16.3 ± 5.1 % larvae correspond-
ing to the severe phenotype for MO-tsl + EDARADD A
mRNA-injected embryos compared to 7.6 ± 3.9 % for MO-
tsl-injected embryos (p = 0.035)). Importantly, both the res-
cue and the worsening phenotypes were sensitive to the
dose of EDARADD mRNA injected, with 50 and 100 pg of
EDARADD mRNA producing significant and equivalent ef-
fects whereas 25 pg EDARADD mRNA leading only to
slight effects (data not shown). Taken together these data
show that the two human isoforms are not functionally
equivalent in this heterologous system.
Discussion
In this case study focused on the two alternative iso-
forms of the EDARADD adaptor, we investigated how a
signaling pathway important for morphological evolution
[22] could evolve functionally by gain and loss of protein
isoforms. This let us characterize the evolution but also
the function of EDARADD A and B isoforms. As some
of our results are of particular interest with respect to
the EDA pathway’s role in development and Human
Ectodermal Dysplasia (HED) disease [23–26]) we first
review and discuss in some detail the interpretation of
our biochemical experiments, before returning to on our
main focus, which is to integrate the later results with
results about isoform evolution.
EDARADD isoforms: activity and regulation
Because previously little was known about the functional
role of EDARADD A isoform, we compared the activity
of both human isoforms in cellulo, using the same cell
lines (HEK cells) as previous studies [19, 20, 23]. HEK
cells are kidney epithelial cells. Even if the EDA pathway
is mainly known for its role in ectodermal cells, EDA
pathway genes are indeed expressed in the kidney (as
well as in other epitheliae without an ectodermal origin,
e.g. lung, intestine) and Edaradd in particular is detected
in HEK cells [19]. We focused on the activation of the
NF-κB pathway as this is the major pathway activated by
EDA [22]. We showed that the A isoform is more active
than the B isoform as, for the same quantity of protein,
the activation of the NF-κB pathway is 2.5 times higher
in a reporter luciferase assay. It is not surprising that
both isoforms are capable of activating the NF-κB path-
way: beside their N-terminal difference, they share the
same functional domains, such as the TRAF binding
sites or the death domain interacting with EDAR (Fig. 1).
The N-terminal part of proteins is often implicated in
protein folding and stability [27], and this might explain
two differences observed between the A and B proteins.
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folding of the N-terminal part, which may then be spe-
cific to each isoform. Since this N-terminal part contains
the binding site for TRAF6 (Fig. 1B), a major interactor
of EDARADD in transducing downstream signaling [27],
a difference in folding may easily turn into the observed
difference in level of activation of the NF-κB pathway.
Second, the N-terminal peptide could affect the protein
stability and explain the difference in steady-state levels.
Linked to this, we showed that the A isoform is down-
regulated by the activation of the pathway, in contrast to
the B isoform. This downregulation of the A protein
level is linked to the activation of the pathway as the
addition of TRAF 6 further enhances the decrease in
protein level. The mechanism for this downregulation is
unclear, but does not seem to involve proteasome-
dependent degradation. Together, these results obtained
in an overexpression system suggested that the human
A and B EDARADD proteins are biochemically different,
despite that they differ only in a very short N-terminal
peptide. However, this difference may impact EDA path-
way activation quantitatively rather than qualitatively.
The rescue experiments performed in vivo in zebrafish
further confirmed this biochemical difference. Before
performing this rescue, we characterized the effects on
zebrafish development of edaradd downregulation by
morpholino injection. The latter resulted in defects of
pharyngeal tooth formation, which could be expected
based on the phenotype observed in teeth of other fishes
[21, 28] and mammals [22]. However, the craniofacial
skeleton was also abnormal. This was in line with eda
and edar expression in the developing craniofacial re-
gion detected from 48 and 24 hpf respectively. Interest-
ingly, both in mouse and human, a mutation in the Eda
gene leading to defects in the craniofacial skeleton has
also been observed [29]. Our results thus highlight an
underappreciated role of the EDA pathway in craniofa-
cial development. We then tested the ability of human A
and B isoforms to rescue this phenotype. The human B
isoform, but not the A isoform, is capable to rescue the
edaradd MO-induced phenotype. Of note, this rescue
observed despite EDARADD B overexpression has no
major effect on zebrafish development. This is reminis-
cent of the results with the K14-Edaradd mice, which
overexpress Edaradd in skin appendages. These mice
display no overt phenotype, yet the transgene can res-
cue the mutant hair follicle and tail kinking phenotype
([30, 31] and D. Headon, personal communication).
This rescue experiment suggests that the B isoform is
functionally closer to the single zebrafish Edaradd pro-
tein and thus probably closer to the ancestral EDAR-
ADD protein predating A isoform gain in mammals.
In contrast, the human isoform A is unable to rescue
the edaradd MO-induced phenotype. Worse, it tendsto enhance phenotype severity. This suggests that the
A protein may exert a dominant negative effect on the
remaining endogenous Edaradd protein. The human A
isoform could compete with the endogenous protein,
but being unable to transduce downstream signaling
in zebrafish. Alternatively, as suggested in cellulo, the
human A isoform could be rapidly destabilized follow-
ing pathway activation and in turn destabilize the
endogenous protein through heteromer formation.
Whatever the explanation, these experiments showed
that the two isoforms are functionally different in vivo.
These differences will have to be further explored
in vivo in mammals. For example, in a near future,
genome-engineering strategies could in principle be
applied to species that possess both isoforms such as
guinea pig.
Finally, we also studied the transcriptional regulation
of the two isoforms. We found that the A promoter ex-
hibits a weak activity in HEK cells whereas the B pro-
moter is more active and exhibits a feedback regulation
following activation of the pathway. Moreover, the B iso-
form is expressed in all tissues and cell lines checked in
this study. In contrast, the A isoform is more often
expressed at lower levels in cell lines and is not found in
some tissues and cell lines. This suggests that the B pro-
moter may drive B isoform expression in all epithelial
tissues making use of the pathway, but be turned off
upon activation of the pathway, whereas the A promoter
may confer to the A isoform a more tissue-restricted ex-
pression, which remains unchanged (at the transcrip-
tional level) when the pathway is activated.
Putting together the transcriptional and post-
transcriptional levels, there are clear regulatory differ-
ences between the two isoforms despite the fact that
both activate the NF-κB pathway. The B isoform is
well expressed, stable, activates NF-κB consistently
and exhibits feedback regulation at the transcriptional
level. The A isoform is expressed in more specific con-
texts, activates NF-κB strongly but is downregulated
by a unknown feedback mechanism at the protein
level. Thus it appears that the two isoforms should en-
able regulating the EDA pathway in a tissue-specific
manner and in different ways, in terms of level of
activation and dynamics. In the context of the devel-
opment of ectodermal appendages, [22, 32], such flexi-
bility of the pathway activation is interesting, as the
level and dynamics of the pathway activation is expected to
have phenotypic consequences on the patterning of ecto-
dermal appendages. Indeed, we know from many examples
of experimental tinkering of the pathway that changes in
activity translate into phenotypic changes in terms of num-
ber, size and shape of ectodermal appendages (e.g. in hair
[33] and teeth [34]), some highly resembling natural species
variation [35, 36].
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pathways by isoforms evolution
Previously, the expansion of signaling pathways reper-
toire was mainly explained by gene or genome duplica-
tion [1] but recent transcriptomic studies revealing the
ubiquity and lability of alternative isoforms [9] suggest
to add the evolution of isoforms as a key mechanism.
EDARADD nicely exemplifies this notion.
We showed that the B isoform is the ancestral isoform
and is conserved in all examined species. Several results
suggest that the B isoform has kept the core, vertebrate-
conserved, functions of EDARADD: i) it is highly similar
at the amino-acid level to the single isoform found in
birds and even in fish ii) the human B isoform is able to
rescue the zebrafish morphant, iii) it is expressed in all
tissues where the pathway is found. In sharp contrast,
the A isoform newly evolved in mammals due to a new
upstream promoter and was repeatedly lost during
mammal diversification. Its expression pattern suggests
a more accessory role than isoform B. Despite that it
also activates the NF-κB pathway as isoform B, it turned
out that it clearly differs from isoform B in terms of
transcriptional and post-translational regulation. There-
fore, our results suggest that this new A isoform brought
new possibilities and levels of regulation to the EDA
pathway, different from B isoform. Moreover, our results
highlight the highly mosaic albeit nonrandom evolution
of A isoform. Indeed, A isoform is present in both mar-
supial and placental mammals (Fig. 2, see also Fig. 4 for
expression) that diverged 165–215 MYA [37], and in
most groups of placental mammals. This contrasts with
the high rate of losses found during late (post- KT
boundary) mammals diversification. This suggests that
the loss of isoform A is specifically associated with
mammal diversification and the underlying extensive di-
versification of their ectodermal appendages (hair, teeth,
glands, nails…) in terms of number and shape. It is not
easy to find a common phenotypic trend in the lists of
species where A isoform is lost. Although we may have
missed it, we rather favor the possibility that the inde-
pendent losses of A isoform are associated with a num-
ber of different phenotypic changes. Indeed, it is likely
that isoform A regulation evolved rapidly along the
mammalian tree together with changes in ectodermal
appendages, the loss in some species being just extreme
cases in which the regulation diverged up to be lost. The
loss could occur either because changes in ectodermal
appendages phenotype made it dispensable or because
the loss participated in reaching an adaptive phenotype.
Conclusions
In summary, as the EDA pathway is a hot spot of adap-
tation [22], it is easy to imagine that by modulating the
level of activation of the EDA pathway through spaceand time, the regulation of these two isoforms (and es-
pecially A) could follow or sometimes allow rapid evolu-
tion of ectodermal appendages. Simultaneously, the two
isoforms (and especially B) could ensure that essential
functions are maintained. If true, this duality between an
ancestral slowly evolving isoform and a newly rapidly
evolving isoform may provide a strong evolvability to the
pathway in terms of spatio-temporal regulation, while
ensuring that essential functions are maintained. This
case study suggests we pay greater attention to mosaic
evolution of isoforms as an important mechanism of
phenotypic change.
Methods
Exon 1A region sequence
The exon 1A region of 24 Mammals (21 rodents, three non-
rodent) was obtained by extracting total genomic DNA from
ethanol-preserved tissues obtained from the collection of
Preserved Mammalian Tissues of the Institut des Sciences
de l’Evolution of Montpellier (France) with a DNeasy Blood
and Tissue extraction kit (Qiagen). The region was then
PCR amplified and sequenced twice independently using
primers F4 AGAARGAACCACARACCAAACCTC and
R4 TTTGGCATTAGTTACTGCCTGACC. Other mam-
mal species sequences were obtained by tBLASTN on
Ensembl genomes and TRACE release 59 (3 August 2010)
accession number are in the Additionnal file 6: Dataset S6.
Sequences were aligned using Muscle (http://www.drive5.-
com/muscle/) [38] followed by manual refinements and
visualized in Seaview (http://pbil.univ-lyon1.fr/soft-
ware/seaview.html). [See dataset in Additional file 6:
Dataset S6].
in vitro translation experiments
Eight exon 1A constructs (Human, Human ATG1 mutant,
Human ATG2 mutant, Human double mutant, Cavia por-
cellus, Equus caballus, Meriones crassus, Vicugnia pacos)
were synthetized (the limits of exon 1A in the different spe-
cies being defined by sequence homology to the human
exon 1A) , cloned in p0Renilla vector and tested by in vitro
translation as [39]. Briefly, p0Renilla-derived vectors contain-
ing a 100 nt long poly(A) tail were linearized by EcoRI diges-
tion. Capped mRNAs were transcribed in vitro 2 h at 37 °C
using 1 μg of linear DNA template; 80 U of T7 RNA poly-
merase (Promega); 40U of RNAsin (Promega); 10 mM of
rCTP, rUTP, rATP; 0.36 mM rGTP; 30 mM DTT; 1.24 mM
of m7GpppG cap analogue (New England Biolabs) in tran-
scription buffer (40 mM Tris–HCl (pH 7.9), 6 mM MgCl2,
2 mM spermidine and 10 mM NaCl). mRNAs were DNase
treated and precipitated with 1 volume of ammonium acet-
ate 5 M (2.5 M final concentration). The integrity of mRNAs
was checked on agarose gel electrophoresis and their con-
centration was quantified by spectrophotometry at 260 nm
using Nanodrop (NanoDrop Technologies, Wilmington,
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for 30 min at 30 °C in 10 μl of the supplemented untreated
RRL or the Flexi® Rabbit Reticulocyte System 50 % (v/v) each
(Promega Co., Madison, WI, USA) in the presence of KCl
(75 mM), MgCl2 (0.5 mM), 20 μM of amino acids mix
minus methionine and 0.6 μCi of [35S]-methionine (GE
Healthcare Life Sciences). Reactions were stopped with 2 ×
SDS-loading buffer and the products were resolved by 15 %
SDS–PAGE. Gels were dried and subjected to autoradiog-
raphy using Biomax films (Eastman Kodak Co.).
Promoter analysis
We amplified by PCR the 5′ region of exon 1A in hu-
man and exon 1B in human and mouse. We took 2900
pb upstream the ATG of the exon 1A for the human A
promoter and the entire region between the end of the
exon 1A and the ATG of the exon 1B for the human B
and mouse B promoters. We used: for human A pro-
moter: FhumA 5′- TGGCACATTCTGAGGCATAG-3′,
RhumA 5′- AAGATGCTCGCTGGTTGTCT-3′; for hu-
man B promoter: FhumB 5′-ATATGCTAGCGCATT
TGCTGTCTTCCTGG-3′, RhumB 5′-GAGACTCGAG




These fragments were cloned into pGL2 basic vector up-
stream luciferase reporter gene to test the ability of the two
putative promoters to initiate the transcription in HEK
cells. HEK cells grown in 24-well plates were then trans-
fected using Exgen500 transfection reagent (Euromedex).
Each well received 400 ng of each promoter cloned in
pGL2basic vector and 100 ng of β-galactosidase expression
plasmid. For the tests with putative activators such as
EDAR, TRAF6 or CYLD, promoter vectors were cotrans-
fected with i) growing amount of EDAR 50, 100 or 200 ng
supplemented by empty pCDNA3, or 200 ng of EDAR
cloned into pCDNA3, or 200 ng of TRAF6 cloned into
pCDNA3 or 200 ng of EDAR and 200 ng of CYLD into
pCDNA3 kindly gifted by Gilles Courtois and supple-
mented by empty pCDNA3. Cells were lyzed 24 h after
transfection and firefly luciferase activities measured
using the Dual-Luciferase Reporter Assay System (Pro-
mega). Normalization for transfection efficiency in lu-
ciferase reporter assays was done by including a
constant amount of a β-galactosidase expression plas-
mid in all transfections and measuring β-galactosidase
activity. Each transfection was performed in triplicate,
and three independent experiments were performed.
RT-PCR experiments
A guinea pig was obtained from Harlan. Treatment satisfied
the requirements of the latest european directive 2010/63.
Euthanasia was performed by a trained and authorizedperson (n°69387512), administrating lethal dose of pento-
barbital. Guinea pig total RNA was extracted from fresh or
RNAlater (sigma) preserved tissues using Qiagen RNA easy
kit. Macropus eugenii RNAs were a kind gift of Dr Kevin
Nicholas (Melbourne University). Human RNA were ob-
tained from Ambion: FirstChoice® Human Total RNA Sur-
vey Panel for brain, mammary gland, kidney and skin. All
RNAs were reverse transcribed using Superscript III Invi-
trogen. PCR fragments were amplified using an exon 1A
specific primer or an exon 1B specific primer and a reverse
primer in exon 5, respectively: F-A TGGTCCCACGCAG-
CACTAGC, F-B 5′-GAGACCCGGGACGAACAGGC-3′,
R 5′-AGGGAGCGCTGTATCTTGAATGGG-3′ for Cavia
porcellus; F-A 5′-ATGGGACTCAGGACTACAAAGCA-




AAC-3′ and R 5′-ACCTGCGCAGAACCTTCTCCACG
TC-3′ for Homo sapiens. Sequences were deposited in
Genebank with the following accession numbers: XXXX.
RNAseq analysis
The following datasets were downloaded from ENCODE
website (http://genome.ucsc.edu/cgi-bin/hgTrackUi?hgsid=
346780313&c=chr1&g=wgEncodeCaltechRnaSeq, human
genome version hg19, GRCh37: GM92.paired.75 nt.;
NHEK.paired.75 nt.200pb; GM78.paired.75 nt.200pb;
H1ES.paired.75 nt.200pb; K562.paired.75 nt.200pb;
MCF7.paired.75 nt.200pb; GM91.paired.75 nt.200pb.
These cells lines were selected because of their rele-
vance regarding the role of the Eda pathway in mam-
mals: GM92, GM78 and GM91 cells are derived from
mammary gland cell line, HE1S cells are derived from
embryonic cell lines, NHEK are derived from epider-
mal keratinocytes, K562 cells are derived from
leukemia and MCF7 cells are derived from mammary
gland carcinoma.
To estimate the number of reads for each exon, we
used the reads mapped on the human genome version
hg 19 on ENCODE website. For each cell line and repli-
cate, we extracted the BAM file corresponding table and
discarded ambiguous reads. We then obtained specific
reads for each exon 1A and 1B and for constitutive exon
6 as a control. As the number of read depends on exon
size, we normalized the number of reads by exon size
(228 bp for exon 1A, 245 bp for exon 1B and 426 bp for
exon 6) and checked that the number of reads was co-
herent by ensuring that exon 1A + exon 1B = exon 6.
True number of reads mapping to exon A and exon B
were compared to expected numbers under the hypothesis
that both isoforms were expressed at the same levels. This
was done in each library, by using Chi-squared test com-
paring observed and expected distributions for the number
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were unambiguous, as the 4 lines showing a significant dif-
ference in expression levels between A and B (NHEK
(p = 10-15), H1ES (10–27), K562 (10–60), MCF7 (10–17)),
also showed a clearly skewed fold change (more than 8–10
times in exon B compared to exon A).
NF-κB reporter assays and Western Blotting
Expression vectors for EDARADD B were kindly gifted
by Asma Smahi and Céline Cluzeau and included 1) Full
coding sequence of human EDARADD B tagged with a
C-terminal myc tag and cloned in pCDNA3.1 and 2) Full
coding sequence of human EDARADD B tagged with a
N-terminal HA tag and cloned in pCDNA 3. We ampli-
fied the EDARADD A N-terminal end by RT-PCR from
human RNA and we used recombination to replace the
sequence encoding the B peptide by the sequence
encoding the A peptide directly in the above mentioned
EDARADD B vectors (InFusion Cloning system, Clonetch).
For NF-κB activation assays, HEK cells grown in 24-
well plates were transfected using Exgen500 transfection
reagent (Euromedex). Each well received 200 ng of
IgKLuc luciferase reporter (Clontech) kindly gifted by
Asma Smahi and Céline Cluzeau as well as the above
EDARADD pcDNA3 vectors and empty pCDNA3 vector
to give 1.0 μg of DNA per well. Normalization for trans-
fection efficiency in luciferase reporter assays was done
by including a constant amount of a β-galactosidase
expression plasmid in all transfections and measuring
β-galactosidase activity. Cells were lyzed 24 h after trans-
fection and luciferase activities measured using the
Dual-Luciferase Reporter Assay System (Promega), ac-
cording to the manufacturer’s protocol. Each transfec-
tion was performed in triplicate, and three independent
experiments were performed.
For Western Blotting, HEK cells grown in 6-well plates
were transfected with 1.5 μg of pCDNA3.1-EDARADD-
myc or empty pCDNA3 or 1.5 μg pCDNA3.1-EDAR-
ADD-myc cotransfected with 750 ng of EDAR or TRAF6
supplemented by empty pCDNA3 using Exgen500 trans-
fection reagent (Euromedex). 24 hours or 48 hours after
transfection, cells were harvested using ice-cold PBS and
lysed in 50 μL of RIPA buffer. Proteins were fractionated
in 12 % SDS/polyacrylamide gel electrophoresis and
transferred to a nitrocellulose membrane. Mouse anti-HA
antibody (1:5000), mouse anti-myc antibody (1:5000) and
rabbit anti-histone H3 (ab1791, Abcam) were used as pri-
mary antibodies and the reactive bands were detected via
an ECL kit (Amersham Life Sciences).
Fish husbandry
Zebrafish and their embryos were handled according to
standard protocols [40] and in accordance with the animal
welfare committees of the Ecole Normale Supérieure deLyon. Zebrafish strains of AB/Tü were reared and staged
at 28.5 °C according to Kimmel and collaborators.
RT-PCR for zebrafish experiments
Total RNA was extracted from 25 embryos at various
time points using the Nucleospin RNA II kit (Macherey-
Nagel) according to the protocol for animal tissues and
1 μg of RNA was reverse-transcribed using Moloney
murine leukemia virus reverse transcriptase (Promega),
followed by amplification of desired cDNA by PCR with
Taq DNA polymerase with ThermoPol buffer (BioLabs).
The ENSEMBL accession number for Danio rerio edar-
add mRNA was ENSDART00000089916. Standard PCR
primers for edaradd mRNA detection and splice blocking
morpholino validation were as follows: For-edaradd, 5′-
GCTCTGTGTTCCCACATCAA-3′; Rev-edaradd, 5′-
ACCAGGAGGAACAGAGCTGA-3′. The actin1 gene
was used as a control: For-β-actin1, 5′-AAGCAGGAG
TACGATGAGTCTG-3′; and Rev-β-actin1, 5′-GGTA
AACGCTCCTGGAATGAC-3′.
Morpholino knockdown
Morpholino oligonucleotides (edaradd MO-tsl (translation
blocking): 5′-CACACATAGAAGAAGATCGTTGATC-3′;
edaradd MO-spl (splice blocking): 5′-CACCAAGCG-
TATTTACTTACCAAAC-3′) and the corresponding mis-
match controls (MO sequence containing five base
mismatches): edaradd MS-tsl: 5′-CAgAgATAcAAGAA-
cATCcTTGATC-3′ and edaraddMS-spl: 5′-CACgAAcCG-
TATaTAgTTAgCAAAC-3′) were supplied by Gene Tools
and diluted in sterile water containing 0.05 % phenol
red. One-cell stage AB/Tü embryos were injected with
0.5 nl of morpholino oligonucleotide dilution (1 mM
for MO-tsl and 2 mM for MO-spl) and then incubated
at 28.5 °C in E3 medium (5 mM NaCl, 0.17 mM KCl,
0.33 mM CaCl2, and 0.33 mM MgSO4). The pheno-
typic observations of morphants were performed with
a stereomicroscope or a light microscope (all from
Leica) equipped with a digital camera. MO-injected
embryos were routinely compared with corresponding
MS-injected, phenol red-injected, and uninjected
embryos.
RNA preparation and rescue experiments
Capped Homo sapiens EDARADD-A and -B and Danio
rerio edaradd were synthesized and purified from
pCS2+:EDARADD-A and B and pCS2+:edaradd plasmids
by using the mMESSAGE mMACHINE Sp6 kit (Ambion).
For the rescue experiments, 25, 50 and 100 pg of capped
human EDARADD-A, −B mRNA or capped zebrafish
edaradd mRNA were co-injected with edaradd MO-tsl at
the one-cell stage. These one-cell stage embryos were co-
injected with MO-tsl and/or capped human EDARADD A
or B mRNA with at least 70 embryos injected per
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phenotype condition and is representative of at least 3
separate experiments with 3 different capped mRNA pro-
ductions. Results are given as the mean ± S.E. The signifi-
cance of differences between mean values was evaluated
by Student t test (*, p < 0.05; **, p < 0.01).
Zebrafish staining and whole mount in situ hybridization
Alcian blue (cartilage) and Alizarin red (bone) double
staining was performed as described [41] with minor
modifications: staining was performed overnight on 5.5
dpf larvae with a solution containing 0.02 % (w/v) Alcian
Blue 8GX, 100 mM MgCl2 and 0.005 % (w/v) Alizarin
red in 70 % EtOH. Larvae were then bleached 20 min in
1.5 % (v/v) H2O2 and 1 % (w/v) KOH and then digested
for 5 min in 1.67 % (w/v) trypsin.
Whole mount in situ hybridization was performed as
previously described [42]. Staging was performing ac-
cording to Kimmel. Sense and antisense RNA probes for
each gene tested were prepared from partial cDNA. The
development of endogenous pigments was inhibited by
exposing embryos to 1-phenyl-2-thiourea (PTU) at a
final concentration of 0.2 mM.
Additional files
Additional file 1: Figure S1. Genomic region of human EDARADD
gene. Genomic region of the EDARADD gene in human (version hg19)
vizualized in the UCSC genome browser (https://genome-euro.ucsc.edu/cgi-
bin/hgTracks?db=hg19&position=chr1%3A236480456-236681365&hgsid=
198526640_PuRKSKevW48nfe6o7ZmzCdqA0Kun). Genomic coordinates are
the following: Chromosome 1: 236,348,262-236,484,914, exon 1A: Chr 1:
236,394,278-236,394,505, exon 1B: Chr 1: 236,395,416-236,395,660. In human
ENCODE 7 cell, exon 1 A and B transcription initiation sites are embedded into
a single H3K27ac peak, an epigenetic mark which is associated with initiation
sites and active enhancers (green arrow). Human EST can be visualized above
the gene organization, with 1A or 1B alternative first exon. Upstream, two
human spliced EST match another H3K27ac peak (red arrow). They are
composed of three exons matching this region and exons 2–6 of EDARADD.
Such a transcript could possibly encode an EDARADD protein (that would
then be initiated with an internal methionine as compared with A and B
proteins, although it is not a consensus kozak sequence: gatcatATGG/gccA/
GccATGG). The functional significance of this putative EDARADD transcript is
however very dubious. Not only ESTs matching these 3 additional exons are
strongly underrepresented in EST databases as compared with EST matching
exons 1A et 1B, but they all come from testis, a tissue which is known for
showing leaky transcription. We thus tend to believe that transcriptional
activity at this site may rather reflect the presence of a distant enhancer of
Edaradd (enhancers are known to be transcribed and show H3K27ac
epigenetic mark as initiation sites) rather than the transcription of protein
coding transcript. We nevertheless investigated the presence of a
homologous transcript in other species. No upstream initiation site is found in
mouse (EST database screening), suggesting that if this upstream H3K27ac
peak corresponds to a third alternative promoter, this promoter is not
conserved in mouse. Parts of the genomic region spanning the H3K27ac peak
are conserved in the cow, but found on another chromosome than EDARADD
(chr8 instead of 28); and no homologous region is found in dog; suggesting
that if there is a third EDARADD alternative promoter, which we find unlikely, it
would not be conserved in mammals. In conclusion, we did not consider this
putative human third EDARADD transcript/promoter in the rest of the
manuscript because its functional significance is dubious and moreover it
does not seem conserved in mammals.Additional file 2: Figure S2. Exon 1 outside mammals. Coding
sequence of exon 1B is well conserved in mammals and even in
vertebrates whereas the one of exon 1A is variable with a frequent loss
of ATG (regarding A isoform, for an augmented dataset, see Fig. 1 and
[Additional file 6 - Dataset S6]).
Additional file 3:Figure S3. EDARADD A and B do not exhibit any
synergic or antagonistic effect for NF-κB activation. EDARADD A and B
were transfected and cotransfected in HEK cells as followed: EDARADD A
300 ng, EDARADD B 300 ng, EDARADD A 200 ng with EDARADD B 100 ng,
EDARADD A 100 ng with EDARADD B 200 ng, EDARADD A 150 ng with
EDARADD B 150 ng. Each time, a NF-κB reporter plasmid that harbors
NF-κB response elements upstream a luciferase reporter gene was
cotransfected. The luciferase activity was normalized against the vector.
The luciferase activity was assayed 24 hours after transfection.
Additional file 4: Figure S4. Details for experimental validation of
edaradd knockdown with morpholinos and edaradd rescue experiments
in zebrafish. A: edaradd mRNA level in zebrafish during embryonic
development. edaradd mRNA level was analyzed by RT-PCR on whole
embryos from 2.5 to 120 hpf. edaradd is highly detected as a maternal
transcript before zygotic transcription starts. At 12 hpf, zygotic edaradd
mRNA transcription starts and increases until 96 hpf. This result is
representative of 3 independent experiments. B: Validation of
Morpholino-induced edaradd downregulation. WT embryos were
injected at one-cell stage with 4 ng translation- (MO-tsl) or 8 ng
splice-blocking edaradd MO (MO-spl) and edaradd mRNA expression was
analyzed by RT-PCR using specific primers to amplify DNA sequence either
side of the targeted splice donor site (between exons 1 and 4) (see Fig. 5A
for primer and morpholino localization). At 48 hpf, we observed an absence
of PCR product in MO-spl-injected embryos when compared to MS-spl-,
MO-tsl- and MS-tsl-injected embryos demonstrating that the MO-spl efficiently
blocked edaradd splicing. As expected, neither injection with translation
blocking MO (MO-tsl) nor with its mutated version (MS-tsl) impacted edaradd
mRNA levels. This result is representative of 3 independent experiments. C:
Knockdown of edaradd expression with MO-tsl or MO-spl. Percentages for
the various phenotypic groups obtained following MO-tsl injection were
determined and are representative of 3 independent experiments; each
experiment was performed with at least 70 injected embryos. D:
Determination of human EDARADD A and B role through rescuing
experiments in zebrafish. One-cell stage embryos were co-injected with
MO-tsl and/or capped human EDARADD A or B or zebrafish edaradd
mRNA. At least 70 embryos were injected per condition and the results are
expressed as the percentage of each phenotypic groups observed per
condition. Results are representative of 6 separate experiments performed
with 2 different batches of mRNA. Statistical analyses have been performed
on the severe phenotypic condition. E: Overexpression of human EDARADD
A or B isoforms or zebrafish Edaradd has no obvious effect on skeletal
development. WT embryos were injected with 100 pg of capped human
EDARADD A or B mRNA or zebrafish edaradd mRNA at one-cell stage and
skeletal morphogenesis was analyzed through alcian blue and alizarin red
staining at 5.5 dpf. A representative ventral view of the head of a larvae is
shown for each condition and a zoom on the teeth is shown on the right
panel (scale bar: 100 μm).
Additional file 5: Figure S5. Expression of Eda and Edar in the
pharyngeal region during zebrafish embryogenesis determined using
whole mount in situ hybridization. A: Coexpression of eda and edar at
60hpf in the pharyngeal region in lateral view (up) and ventral view
(low). B: Expression pattern of eda from 48 to 80 hpf. For each stage a
lateral view is shown with, as an inset, a ventral view. No expression was
detected before 48hpf. C: Expression pattern of edar from 24 to 80 hpf.
For each stage a lateral view is shown with, as an inset, a ventral view.
No expression was detected before 24 hpf.
Additional file 6: Dataset S6. Sequences dataset of the exon 1A
region. Alignment of the exon 1A region obtained by BLAST or
sequencing (see material and method for details) in Seaview software.
Human TSS (Transcription Start Site) and the two ATG are annotated.Competing interests
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